The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19

被引：23

作者：

Focosi, Daniele ^{[1
]}

Tuccori, Marco ^{[2
,3
]}

Franchini, Massimo ^{[4
]}

机构：

[1] Pisa Univ Hosp, North Western Tuscany Blood Bank, I-56124 Pisa, Italy

[2] Univ Pisa, Div Pharmacol & Pharmacovigilance, I-56126 Pisa, Italy

[3] Pisa Univ Hosp, Unit Adverse Drug React Monitoring, I-56124 Pisa, Italy

[4] Carlo Poma Hosp, Dept Hematol & Transfus Med, I-46100 Mantua, Italy

来源：

LIFE-BASEL | 2021年 / 11卷 / 02期

关键词：

COVID-19; SARS-CoV-2; polyclonal immunoglobulins; convalescent plasma; Cohn’ s fractionation; IgG; passive immunotherapy; INTRAVENOUS IMMUNOGLOBULIN; NEUTRALIZING ANTIBODIES; INACTIVATION; INFECTION; GLOBULIN; VIRUSES; SAFETY;

D O I：

10.3390/life11020144

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted emergency use authorization, have suggested benefit in early disease course (less than 72 hours from symptoms and seronegative). Meanwhile, polyclonal immunoglobulins (i.e., hyperimmune serum), derived either from CCP donations or from animals immunized with SARS-CoV-2 antigens, are likely to become the next nAb-derived candidate. We here discuss the pros and cons of hyperimmune serum versus CCP and mAb, and summarize the ongoing clinical trials of COVID-19 hyperimmune sera.

引用

页码：1 / 9

页数：8

共 40 条

[31] Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection [J].

Sanders, Sharon L. ;

Agwan, Sushil ;

Hassan, Mohamed ;

van Driel, Mieke L. ;

Del Mar, Chris B. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (08)

[32] Anti-thymocyte globulin in haematology: Recent developments [J].

Siddiqui, Salahuddin ;

Cox, Jessica ;

Herzig, Roger ;

Palaniyandi, Senthilnathan ;

Hildebrandt, Gerhard C. ;

Munker, Reinhold .

INDIAN JOURNAL OF MEDICAL RESEARCH, 2019, 150 (03) :221-227

[33]

Suthar MS, 2020, CELL REP MED, V1, DOI [10.1016/j.xcrm.2020.100040, 10.1101/2020.05.03.20084442]

[34] Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline [J].

Tuccori, Marco ;

Ferraro, Sara ;

Convertino, Irma ;

Cappello, Emiliano ;

Valdiserra, Giulia ;

Blandizzi, Corrado ;

Maggi, Fabrizio ;

Focosi, Daniele .

MABS, 2020, 12 (01)

[35]

Vandeberg P., 2020, TRANSFUSION, DOI [10.1101/2020.11.18.388991, DOI 10.1101/2020.11.18.388991]

[36]

Vanhove B., 2020, POTENT NEUTRALIZING, DOI [10.1016/j.biologicals.2005.01.003, DOI 10.1016/J.BIOLOGICALS.2005.01.003]

[37] Robust neutralizing antibodies to SARS-CoV-2 infection persist for months [J].

Wajnberg, Ania ;

Amanat, Fatima ;

Firpo, Adolfo ;

Altman, Deena R. ;

Bailey, Mark J. ;

Mansour, Mayce ;

McMahon, Meagan ;

Meade, Philip ;

Mendu, Damodara Rao ;

Muellers, Kimberly ;

Stadlbauer, Daniel ;

Stone, Kimberly ;

Strohmeier, Shirin ;

Simon, Viviana ;

Aberg, Judith ;

Reich, David L. ;

Krammer, Florian ;

Cordon-Cardo, Carlos .

SCIENCE, 2020, 370 (6521) :1227-+

[38] RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations [J].

Wasserman, Richard L. ;

Greener, Benjamin N. ;

Mond, James .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (12) :1107-1119

[39]

WHO, 2007, WHO TECH REP SER, p189

[40]

Zylberman V, 2020, MEDICINA-BUENOS AIRE, V80, P1

← 1 2 3 4 →